HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

thiazolidine-2,4-dione

structure in first source
Networked: 8 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Vikram, Ajit: 1 article (12/2015)
2. Mughal, Amreen: 1 article (12/2015)
3. Kumar, Dinesh: 1 article (12/2015)
4. Kaur, Maninder: 1 article (07/2015)
5. Silakari, Om: 1 article (07/2015)
6. Bahia, Malkeet Singh: 1 article (07/2015)
7. Chadha, Navriti: 1 article (07/2015)
8. Watanabe, K: 1 article (01/2015)
9. Hamada, K: 1 article (01/2015)
10. Matsumoto, T: 1 article (01/2015)

Related Diseases

1. Neoplasms (Cancer)
01/01/2015 - "Furthermore, treatment with the newly synthesized thiazolidine-2,4-dione congener, 12a-OH, as well as its prototypic SMI-16a effectively prevented bone destruction while suppressing MM tumor growth in MM animal models. "
12/05/2015 - "Structural analysis of TZDs suggest that the presence of 5-exo C-C single bond of the thiazolidine-2,4-dione ring is important for the metabolic effects but not for anti-cancer effects, as inclusion of C=C double bond at this position promotes antagonistic properties to the PPARĪ³ receptor without compromising its anti-proliferative effects. "
05/01/2013 - "Molecules bearing a thiazolidine-2,4-dione scaffold have been recognized as antineoplastic agents with a broad spectrum of activity against many cancer cell lines. "
04/01/2013 - "The promising activity shown by compounds containing thiazolidine-2,4-dione nucleus in numerous categories such as anti-hyperglycaemics, aldose reductase inhibitors, anti-cancer, anti-inflammatory, anti-arthritics, anti-microbials, etc. has made it an indispensable anchor for development of new therapeutic agents. "
07/01/2015 - "Thiazolidine-2,4-dione is an extensively explored heterocyclic nucleus for designing of novel agents implicated for a wide variety of pathophysiological conditions, that is, diabetes, diabetic complications, cancer, arthritis, inflammation, microbial infection, and melanoma, etc. The current paradigm of drug development has shifted to the structure-based drug design, since high-throughput screenings have continued to generate disappointing results. "
2. Atherosclerosis
3. Diabetes Complications
4. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
5. Prostatic Neoplasms (Prostate Cancer)

Related Drugs and Biologics

1. Hydroxamic Acids (Hydroxamic Acid)
2. Hydrogen
3. Antineoplastic Agents (Antineoplastics)
4. Aldehyde Reductase (Aldose Reductase)
5. 4- (3- (1- adamantyl)- 4- hydroxyphenyl)- 3- chlorocinnamic acid
6. single bond
7. 1H-tetrazole (tetrazole)